斯丹赛生物技术有限公司宣布圆满完成与FDA的新药临床试验申请前（Pre-IND）会议
April 09, 2019 21:00 ET
|
Innovative Cellular Therapeutics
中国上海及美国马里兰州罗克维尔, April 10, 2019 (GLOBE NEWSWIRE) -- 斯丹赛生物技术有限公司（Innovative Cellular...
Innovative Cellular Therapeutics Announces Successful Completion of Pre-IND Meeting With FDA
March 19, 2019 08:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced it...
Pet Cancer Therapeutics Market to hit $359.4 Million by 2025: Global Market Insights, Inc.
March 15, 2019 03:04 ET
|
Global Market Insights, Inc
Sellbyville, Delaware, March 15, 2019 (GLOBE NEWSWIRE) -- Australian pet cancer therapeutics market is forecast to grow at over 12.6% CAGR in given timeframe. High growth is due to growing...
Innovative Cellular Therapeutics Announces Opening of U.S. Office and Appointment of New Members to Executive Leadership Team
March 06, 2019 17:00 ET
|
Innovative Cellular Therapeutics
ROCKVILLE, Md., March 06, 2019 (GLOBE NEWSWIRE) -- Innovative Cellular Therapeutics (ICT), a biotechnology company developing cellular immunotherapies for the treatment of cancer, today announced...
Ett nytt studieresultat med AroCell TK 210 ELISA vid prostatacancer har accepterats för publicering
February 25, 2019 02:30 ET
|
AroCell AB
Studien med titeln “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous conditions”,...
New study results with AroCell TK 210 ELISA in prostate cancer has been accepted for publication
February 25, 2019 02:30 ET
|
AroCell AB
The study with the title “The combination of AroCell TK 210 ELISA with Prostate Health Index (PHI) or PSA density can improve the ability to differentiate prostate cancer from non-cancerous...
Devimistat (CPI-613®) to be Explored in a New Combination for T-Cell Lymphoma Treatment as Part of Stand Up To Cancer’s T-Cell Lymphoma “Dream Team Research Grant”
February 07, 2019 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Feb. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that...
Viracta Announces Scientific Advisory Board Formation
September 25, 2018 08:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other...
New Publication from AroCell AB Demonstrating the Value of Thymidine Kinase 1 as a Tumor Biomarker
August 24, 2018 07:50 ET
|
AroCell AB
A new review article has been published, Thymidine Kinase 1 as a tumor biomarker: technical advances offer new potential to an old biomarker, that analyses and summarizes recent publications...
Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma
August 13, 2018 11:15 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the activation of a second clinical...